Table. Baseline Characteristics and Clinical Evolution of Patients With and Without ARAs at Month 12.
| Characteristics | No. (%) | P value | |
|---|---|---|---|
| With ARAs (n = 13) | Without ARAs (n = 20) | ||
| Age, mean (SD), y | 55 (17) | 56 (17) | .99 |
| Female | 11 (85) | 9 (45) | .03 |
| Male | 2 (15) | 11 (55) | |
| PDAI score, mean (SD) | 30 (26) | 28 (25) | .80 |
| Type of pemphigus | |||
| Foliaceus | 1 (8) | 4 (20) | .33 |
| Vulgaris | 12 (92) | 16 (80) | .33 |
| Mucosal | 4 (33) | 4 (25) | NA |
| Mucocutaneous | 7 (58) | 11 (69) | NA |
| Cutaneous | 1 (8) | 1 (6) | NA |
| Anti-DSG1, mean (SD), AU/mLa | 121 (138) | 253 (328) | .18 |
| Anti-DSG3, mean (SD), AU/mLa | 1093 (1350) | 465 (517 | .11 |
| Incomplete B-cell depletion (CD19+ B cells >0.5%)b | 6 (46) | 5 (25) | .21 |
| Clinical evolution | |||
| Sustained CR until mo 36 | 11 (85) | 20 (100) | .15 |
| Relapse | 2 (15) | 0 | .07 |
Abbreviations: ARA, antirituximab antibody; AU, arbitrary unit; DSG, desmoglein; NA, not applicable; PDAI, pemphigus disease area index.
a
Measured at baseline using enzyme-linked immunosorbent assay.
b
Measured at month 18 (6 months after the month 12 infusion of rituximab).